Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Role of biomarkers, targeted therapy and tumour mutations in the landscape of bladder cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 30.09.19
Views: 3262

Prof Petros Grivas and Dr Michiel Van der Heijden

Prof Petros Grivas (University of Washington School of Medicine, Seattle, USA) and Dr Michiel Van der Heijden (Netherlands Cancer Institute, Amsterdam, Netherlands) discuss the role of biomarkers, targeted therapy and tumour mutations in patients with bladder cancer at ESMO 2019

Prof Van der Heijden discusses the clinical use of PDL-1 as a biomarker for these patients, in which an association was detected at baseline. The experts also explore the use of other biomarkers such as tumour mutation burdens and expression patterns in this disease setting.

The experts also discuss the possibility of using a multi-omics approach, whereby different biomarkers could integrated and used as a qualitative method.

Prof Grivas and Dr Van der Heijden conclude by discussing the latest advances in targeted therapy and the main targets for therapy - including FGF receptor mutations.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Role of biomarkers in the neoadjuvant setting
Recent developments in metastatic disease
DNA damage repair gene mutations and response to immunotherapy
Integrating biomarkers using a multi-omics approach
Targeted therapies in urothelial cancer
Optimal biomarkers for FGF-receptor inhibition
Latest drug developments for the third-line setting


Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation